Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Day One Biopharmaceuticals (DAWN) over the last 5 years, with Dec 2024 value amounting to $92,000.

  • Day One Biopharmaceuticals' Depreciation & Amortization (CF) rose 462.50% to $90,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $313,000, marking a year-over-year increase of 367.16%. This contributed to the annual value of $92,000 for FY2024, which is 155.56% up from last year.
  • As of FY2024, Day One Biopharmaceuticals' Depreciation & Amortization (CF) stood at $92,000, which was up 155.56% from $36,000 recorded in FY2023.
  • Day One Biopharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $92,000 for FY2024, and its period low was $16,000 during FY2020.
  • Over the past 3 years, Day One Biopharmaceuticals' median Depreciation & Amortization (CF) value was $63,000 (recorded in 2022), while the average stood at $63,667.
  • In the last 5 years, Day One Biopharmaceuticals' Depreciation & Amortization (CF) spiked by 215.00% in 2022 and then plummeted by 42.86% in 2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $16,000 in 2020, then climbed by 25.00% to $20,000 in 2021, then spiked by 215.00% to $63,000 in 2022, then slumped by 42.86% to $36,000 in 2023, then spiked by 155.56% to $92,000 in 2024.